Assessing Upadacitinib Treatment in Adults with Inflammatory Bowel Disease in Belgium

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the long-term effectiveness and safety of upadacitinib in adult patients with moderate to severe ulcerative colitis and Crohn's disease in Belgium. Approximately 280 participants will be enrolled from 8 sites, receiving upadacitinib as prescribed by their physicians in routine clinical practice. Participants will be monitored for up to 3 years to gather data on treatment outcomes without any additional burden from the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with a diagnosis of moderate to severe Crohn's disease or Ulcerative colitis, initiated with upadacitinib at least 12 months prior to inclusion, including participants that were initiated on upadacitinib, but later (i.e. at the moment of data collection) discontinued, or switched to another treatment.
* Participants initiating commercially available upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study
* Participants prescribed upadacitinib in accordance with the approved local label and treatment recommendations

Exclusion Criteria:

* Participants previously exposed to upadacitinib in a clinical trial or early access program
* Participants participating in interventional research (not including non-interventional
* Participants with stoma

Where it's running

• Imelda Ziekenhuis /ID# 268631
  Bonheiden, Antwerpen, Belgium Recruiting
• Universite Libre de Bruxelles - Hopital Erasme /ID# 268632
  Anderlecht, Brussels Capital, Belgium Recruiting
• Chu De Charleroi - Hopital Civil Marie Curie /ID# 284063
  Lodelinsart, Hainaut, Belgium Recruiting
• Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 284064
  Tournai, Hainaut, Belgium Recruiting
• Groupe Sante CHC - Clinique du MontLegia /ID# 268662
  Liège, Liege, Belgium Recruiting
• Ziekenhuis Oost-Limburg, Campus St.-Jan /ID# 283334
  Genk, Limburg, Belgium Recruiting

Study contacts

• Study coordinator: Liesbeth Ghys
• Email: liesbeth.ghys@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating Upadacitinib for Inflammatory Bowel Disease

  This study is testing how well the oral medication Upadacitinib works for people in China with Inflammatory Bowel Disease who haven't responded to other treatments.

  Recruiting at 6 sites Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT06780683

• Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults

  This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.

  Recruiting at 66 sites Phase 2 AbbVie · Dothan, Alabama and 65 other locations · NCT07697456

• Longitudinal Immunophenotyping of People with Inflammatory Bowel Disease

  This study will follow adults with Crohn's disease or ulcerative colitis (and some healthy relatives) over three years to see how their immune cells change over time and how genetics and diet relate to their disease.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619547

• Pregnancy in people with inflammatory bowel disease

  This project will see if pregnancy changes how often women with IBD have disease flares by analyzing registry data from women who had pregnancies.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07377188

• Second-line treatment with upadacitinib or risankizumab for adults with Crohn's disease

  This project will test how well upadacitinib or risankizumab work as second-line treatments for adults with moderate-to-severe Crohn's disease who previously used a TNF inhibitor.

  Recruiting at 25 sites AbbVie · Castellana Grotte, Bari and 24 other locations · NCT07073079

• Evaluating Upadacitinib for Ulcerative Colitis in Chinese Adults

  This study is testing how well upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis.

  Recruiting at 3 sites AbbVie · Guangzhou, Guangdong and 2 other locations · NCT06838845

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.